This medication is indicated in states of vitamin B12 deficiency such as: pernicious anemia (reduction in the number of red blood cells due to vitamin B12 deficiency), pregnancy, malabsorption syndrome (difficulty in digesting nutrients from food that may be accompanied by diarrhea and colic), sprue (inflammation of the small intestine due to intolerance to gluten and other grains, causing diarrhea), regional enteritis (chronic inflammation of the digestive tract, small intestine, and colon), intestinal or pancreatic neoplasms (tumors), total or partial gastrectomy (removal of all or part of the stomach), and other conditions where there is a significant increase in the requirements of this vitamin
Clinical and Research Dosing Phase 3 Clinical Trial Dose: The standard dose used in Phase 3 trials for PMM and Heart Failure research is 40 mg SubQ once daily
Prsence ou non de troubles gastriques ou de malabsorption
Incorporate this injection as prescribed for optimal health support and vitality
Today, AOD-9604 remains a topic of scientific interest, not as an approved therapy, but as a case study in how translational challenges can derail promising preclinical results
